Teva to Present Data Highlighting SD-809 at 20th International Congress of Parkinson’s Disease and Movement Disorders

Data in Huntington Disease, Tardive Dyskinesia and Tourette Syndrome to Be Presented

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced new data for SD-809 (deutetrabenazine) tablets will be presented at the 20th International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Berlin, June 19-23, 2016.

Teva-sponsored data evaluating SD-809 in patients with chorea associated with Huntington disease, tardive dyskinesia and tics associated with Tourette syndrome will be highlighted in clinical, preclinical and health economics data poster presentations. In addition, Teva will host a Corporate Symposium entitled, “Emerging Technologies and Therapies in Movement Disorders,” on Thursday, June 23, 2016 from 1:30 to 2:30 p.m. CEST.

“There is a significant unmet medical need, as limited options are currently available for the treatment of neurological disorders such as Huntington disease, tardive dyskinesia and Tourette syndrome,” said Michael Hayden, MD, PhD, President of Global R&D and Chief Scientific Officer at Teva. “Data planned for presentation at this year’s MDS Congress demonstrates Teva’s commitment to research and helping improve the lives of patients and caregivers in these severely underserved patient communities.”

Teva-sponsored data to be presented include:

  • Evaluation of Quality of Life (QoL), Patient- and Clinician-Reported Outcomes with Deutetrabenazine Treatment of Chorea in Huntington Disease in First-HD (C. Testa, D. Claassen, D. Oakes, D. Stamler, V. Sung, S. Frank)
  • Alternatives for reducing chorea in Huntington disease, a long-term trial (ARC-HD): Updated Week 8 results for the switch cohort (D. Stamler)
  • Maintenance of balance function in patients with HD treated with deutetrabenazine, as measured by Berg balance test (BBT) in First-HD (D. Claassen, D. Oakes, D. Stamler, V. Sung, C. Testa, S. Frank)
  • Evaluating Swallowing Function in Patients with Huntington Disease Enrolled in the First-HD Study (D. Claassen, S. Frank, V. Sung, S. Janicki, C. Vaughan, D. Stamler, D. Oakes, C. Testa)
  • A randomized, double-blind, placebo-controlled trial of deutetrabenazine for the treatment of tardive dyskinesia (ARM-TD) (H. Fernandez, S. Factor, R. Hauser, J. Jimenez-Shahed, W. Ondo, M. LeDoux, D. Shprecher, T. Simuni, D. Stamler, K. Anderson)
  • A Randomized Double-blind Placebo- and Positive-Controlled Crossover Study to Evaluate the Effects of Single Doses of SD-809 (Deutetrabenazine) and Tetrabenazine on the Corrected QT Interval (D. Stamler, E. Offman, M. Bradbury, L. De Boer)
  • A Pilot Study of SD-809 (deutetrabenazine) in Tics Associated with Tourette Syndrome (J. Jankovic, J. Jimenez-Shahed, C. Budman, B. Coffey, T. Murphy, D. Shprecher, D. Stamler)
  • Indirect comparison of tolerability of deutetrabenazine and tetrabenazine in the First-HD and TETRA-HD trials (D. Claassen, B. Carroll, L. De Boer, E. Wu, R. Ayyagari, S. Gandhi, D. Stamler)
  • Temporal course of the UHDRS chorea score in Huntington disease (T. Felong, P. Auinger, S. Gandhi, V. Abler, K. Biglan, S. Papapetropoulous, C. Venuto, R. Dorsey)
  • Temporal course of the Total Motor Score in Huntington disease (P. Auinger, T. Felong, S. Gandhi, V. Abler, K. Biglan, S. Papapetropoulous, C. Venuto, R. Dorsey)
  • Epidemiology and economic burden of falls and fractures in patients with Huntington's disease (D. Claassen, P. Donga, S. Rajagopalan, L. De Boer, B. Carroll, S. Gandhi)

About SD-809

SD-809 (deutetrabenazine) is an investigational, oral, small-molecule inhibitor of vesicular monoamine 2 transporter, or VMAT2, that is being developed for the treatment of chorea associated with Huntington disease (HD). Deutetrabenazine has been granted Orphan Drug Designation for the treatment of HD by the U.S. Food and Drug Administration (FDA). Teva is also investigating the potential of deutetrabenazine for treating tardive dyskinesia, for which the FDA has granted a breakthrough therapy designation, and for tics associated with Tourette syndrome, for which the FDA has granted orphan status for pediatric use. Deutetrabenazine uses Teva’s deuterium technology.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 amounted to $19.7 billion. For more information, visit

Teva's Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements, which are based on management’s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products; competition for our specialty products, especially Copaxone® (which faces competition from orally-administered alternatives and a generic version); our ability to consummate the acquisition of Allergan plc’s worldwide generic pharmaceuticals business (“Actavis Generics”) and to realize the anticipated benefits of such acquisition (and the timing of realizing such benefits); the fact that following the consummation of the Actavis Generics acquisition, we will be dependent to a much larger extent than previously on our generic pharmaceutical business; potential restrictions on our ability to engage in additional transactions or incur additional indebtedness as a result of the substantial amount of debt we will incur to finance the Actavis Generics acquisition; the fact that for a period of time following the consummation of the Actavis Generics acquisition, we will have significantly less cash on hand than previously, which could adversely affect our ability to grow; the possibility of material fines, penalties and other sanctions and other adverse consequences arising out of our ongoing FCPA investigations and related matters; our ability to achieve expected results from investments in our pipeline of specialty and other products; our ability to identify and successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; the extent to which any manufacturing or quality control problems damage our reputation for quality production and require costly remediation; increased government scrutiny in both the U.S. and Europe of our patent settlement agreements; our exposure to currency fluctuations and restrictions as well as credit risks; the effectiveness of our patents, confidentiality agreements and other measures to protect the intellectual property rights of our specialty medicines; the effects of reforms in healthcare regulation and pharmaceutical pricing, reimbursement and coverage; competition for our generic products, both from other pharmaceutical companies and as a result of increased governmental pricing pressures; governmental investigations into sales and marketing practices, particularly for our specialty pharmaceutical products; adverse effects of political or economic instability, major hostilities or acts of terrorism on our significant worldwide operations; interruptions in our supply chain or problems with internal or third-party information technology systems that adversely affect our complex manufacturing processes; significant disruptions of our information technology systems or breaches of our data security; competition for our specialty pharmaceutical businesses from companies with greater resources and capabilities; the impact of continuing consolidation of our distributors and customers; decreased opportunities to obtain U.S. market exclusivity for significant new generic products; potential liability in the U.S., Europe and other markets for sales of generic products prior to a final resolution of outstanding patent litigation; our potential exposure to product liability claims that are not covered by insurance; any failure to recruit or retain key personnel, or to attract additional executive and managerial talent; any failures to comply with complex Medicare and Medicaid reporting and payment obligations; significant impairment charges relating to intangible assets, goodwill and property, plant and equipment; the effects of increased leverage and our resulting reliance on access to the capital markets; potentially significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; variations in patent laws that may adversely affect our ability to manufacture our products in the most efficient manner; environmental risks; and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2015 and in our other filings with the U.S. Securities and Exchange Commission (the "SEC"). Forward-looking statements speak only as of the date on which they are made and we assume no obligation to update or revise any forward-looking statements or other information, whether as a result of new information, future events or otherwise.

For Teva Pharmaceutical Industries Ltd.:
IR Contacts:
Kevin C. Mannix, 215-591-8912
United States
Ran Meir, 215-591-3033
United States
Tomer Amitai, 972 (3) 926-7656
PR Contacts:
Iris Beck Codner, 972 (3) 926-7687
Denise Bradley, 215-591-8974
United States
Nancy Leone, 215-284-0213
United States